Plasticell

Plasticell announces grant of fundamental CombiCult patents in U.S. and Japan

Monday, February 13, 2012 02:57 PM

Patents for CombiCult, combinatorial cell culture platform technology, have been granted in the U.S. and Japan, according to Plasticell, a biotechnology company specializing in high throughput technologies for directed stem cell differentiation.

More... »


Plasticell honored at R&D 100 Awards

Wednesday, November 2, 2011 12:51 PM

For almost 50 years, the R&D 100 Awards have been recognizing the year’s best new high-technology products. Determined by a panel of experts chosen by R&D Magazine, the award is recognition that the selected product is one of the most important innovations of the year. Plasticell's CombiCult was chosen as one of the hundred for 2011, which included only three technologies from the U.K.

More... »


Progentior Labs voted Best Emerging Biotech

Wednesday, October 12, 2011 11:13 AM

Progenitor Labs, the biotechnology company spun out of Plasticell in 2011, is pleased to announce it has been voted Best Emerging Biotech at the Oxford Biotechnology Network’s Annual Awards Dinner held at Pembroke College, Oxford. Progenitor was selected from the biotechnology companies clustered within the “Golden Triangle” comprising London, Oxford and Cambridge.

More... »

Plasticell wins R&D 100 award

Wednesday, June 29, 2011 12:44 PM

Plasticell, a biotechnology company specializing in high-throughput technologies for directed stem cell differentiation, has won the R&D 100 Award for its CombiCult v2.0 system.

More... »

Plasticell demerges to create regenerative drug discovery unit

Wednesday, April 13, 2011 12:41 PM

London-based Plasticell, the biotechnology company developing stem cell technologies, has undergone a strategic re-structuring to enable the company to focus on its award winning CombiCult technology for stem cell differentiation. Consequently, Plasticell has demerged its regenerative drug discovery unit into a newly established company, Progenitor Labs.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs